Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance also allowed sellers to keep exiting the…
thinkstockApril 9, 2014: Markets opened higher on Wednesday and then got a jolt higher following the afternoon release of the FOMC’s last meeting minutes. The minutes indicated to many investors and traders…
Paul Ausick ThinkstockThe short interest data for the first two weeks of March is out, and the results among the top high-yield safe dividend stocks are mixed. The biggest changes took place in the…
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone rangers when it came to the…
thinkstockMarch 25, 2014: Markets opened higher on Tuesday but dipped sharply in the late morning on weakness in consumer discretionary, financial, and biotech stocks. The Dow and the S&P 500 held on…
thinkstockMarch 24, 2014: Markets opened slightly higher on Monday but soon took a turn south and spent most of the day solidly down. Biotechs, healthcare, discretionary, and tech stocks were all weaker…
Paul Ausick thinkstockMarch 21, 2014: Markets opened higher on Friday but the Nasdaq sank quickly, bounced for a while, and finally settled solidly lower. It took the Dow and the S&P 500 until noon…
Endocyte is trading like it is being acquired. This is proof that any biotech with great cancer drug news can run, regardless of market conditions. One has to wonder if Endocyte is…
Jon C. Ogg States, often burdened by budget deficits that grew during the recession, are not getting tax receipts from some of America's largest companies. Among them are Boeing and Merck, which did not pay…
ThinkstockThe short interest data for the final two weeks of February is out, and the results are somewhat surprising when it comes to the top high-yield safe dividends out there. Some of…
The pricier the stock market gets, the more important it is for investors to keep a close eye on what they are paying for stocks. Flashy momentum stocks are great for traders,…
In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the Cowen 2014 Healthcare Conference by large cap pharmaceutical companies concerning upcoming events…
Novartis announced Monday morning that it will acquire privately held startup biotech CoStim Pharmaceuticals. Terms of the deal were not revealed, but it will bolster Novartis's cancer immunotherapy portfolio.
Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to dazzle. But shares traded higher in the premarket session.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, February 4, 2014. They include Chevron, Gap, Merck, Microsoft and Zynga.
